Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Link opens in a new tab
Search content at Penn State
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
A new era of immunotherapy in prostate cancer
Christopher Pizzola
, Syed M. Rizvi
,
Monika Joshi
Department of Medicine
Penn State Cancer Institute
Cancer Institute, Experimental Therapeutics
Division of Hematology and Oncology
Research output
:
Contribution to journal
›
Review article
›
peer-review
5
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'A new era of immunotherapy in prostate cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Prostate Cancer
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Sipuleucel-T
100%
Immune Checkpoint Inhibitors
66%
Viral
33%
Clinical Trials
33%
In Cancer
33%
Risk Factors
33%
Immune Response
33%
Programmed Death-ligand 1 (PD-L1)
33%
Prostate Cancer Cells
33%
Novel Agents
33%
Tumor Microenvironment
33%
Favorable Risk
33%
Cancer Types
33%
Cancer Vaccine
33%
Ipilimumab
33%
Symptomatic Patients
33%
Indoleamine 2,3-dioxygenase Inhibitor
33%
Visceral Disease
33%
Metastatic Setting
33%
Personalized Peptide Vaccine
33%
Immune Therapy
33%
Anti-PD-1 Monoclonal Antibody
33%
Medicine and Dentistry
Prostate Cancer
100%
Immunotherapy
100%
Sipuleucel T
75%
Immune Checkpoint Inhibitor
50%
Malignant Neoplasm
25%
Monoclonal Antibody
25%
Clinical Trial
25%
Disease
25%
Cancer Cell
25%
Programmed Cell Death
25%
Tumor Microenvironment
25%
Immune Response
25%
Cancer Types
25%
Cancer Vaccine
25%
Ipilimumab
25%
Indoleamine 2,3 Dioxygenase Inhibitor
25%
Peptide Vaccine
25%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Immunotherapy
100%
Sipuleucel T
75%
Malignant Neoplasm
50%
Immune Checkpoint Inhibitor
50%
Clinical Trial
25%
Disease
25%
Tumor Microenvironment
25%
Monoclonal Antibody
25%
Programmed Cell Death
25%
Cancer Vaccine
25%
Indoleamine 2,3 Dioxygenase Inhibitor
25%
Ipilimumab
25%
Peptide Vaccine
25%
Immunology and Microbiology
Vaccine Efficacy
100%
Immunotherapy
100%
Sipuleucel-T
75%
Immune Response
25%
Monoclonal Antibody
25%
Cancer Cell
25%
Indoleamine 2,3-dioxygenase
25%
Cancer Vaccine
25%
Peptide Vaccine
25%
Ipilimumab
25%
Programmed Cell Death 1
25%